Logo
ABBV logo
AbbVie Inc.
ABBV
207.94 (-2.10%) 4.37
Health Care
Biotechnology
AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacturing commercializing and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox Cosmetic for the treatment of glabellar lines crow's feet forehead lines and platysma bands; Juvederm Collection to treat volume loss in the temples undereye cheeks chin lips and lower face; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations as well as Botox Therapeutic to treat chronic migraine overactive bladder spasticity cervical dystonia and other conditions. In addition the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products including Refresh/Optive Xen Durysta and Restasis. Further it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Quality Checklist 1/8

Est. EPS Growth > 5%
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $367.80(B)
EV: $408.14(B)
Total Equity: $-3.23(B)
Earnings date: Apr-29-2026
P/E: 87.74
Forward P/E: 14.33
P/FCF: 20.63
P/S: 6.02
P/B: N/A
EPS: $2.4
EPS (fwd): $14.5
FCF/share: $10.1
Revenue/share: $34.6
Book value/share: $-1.9
ROIC: 3.3%
ROA: 1.7%
ROE: 140.9%
Debt/Equity: 48
Current Ratio: 0.70
Gross margin: 71.6%
Operating margin: 24.1%
Net margin: 6.9%
Dividend/share: $6.7
Div. yield: 3.20%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.12%
Institutions: 76.40%
Other: 23.48%

Institutional ownership

10.22% Vanguard Group Inc8.55% Blackrock Inc.4.58% State Street Corporati...2.96% JPMORGAN CHASE & CO2.52% Geode Capital Manageme...2.26% Morgan Stanley1.46% Bank of America Corpor...1.45% NORGES BANK1.44% Capital Research Globa...1.42% Charles Schwab Investm...39.54% Others

Trading Summary

In the past year, insiders have bought $0.00 worth of the company's stock, and sold $21.79(M).

Congress members have bought between $35021 - $350000 worth of the company's stock, and sold between $96019 - $440000.

Insider transactions

$0.002026-05$0.00
$0.002026-04$0.00
$5.60(M)2026-03$0.00
$5.15(M)2026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$11.05(M)2025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2026-03-045,2301,221,519233.6PURDUE DAVID R.Officer
Sell2026-03-0218,6684,375,549234.4SIATIS PERRY C.General Counsel
Grant2026-02-2522,3813,863,458172.6SIATIS PERRY C.General Counsel
Sell2026-02-2522,3815,147,630230.0SIATIS PERRY C.General Counsel
Grant2026-02-1836,81100.0SALEKI-GERHARDT AZITAChief Operating Officer
Grant2026-02-1848,83800.0REENTS SCOTT T.Chief Financial Officer
Grant2026-02-1833,51800.0SIATIS PERRY C.General Counsel
Grant2026-02-1853,74900.0STEWART JEFFREY RYANOfficer
Grant2026-02-1829,05700.0DONOGHOE NICHOLASOfficer
Grant2026-02-1882,43900.0MICHAEL ROBERT A.Chief Executive Officer
Grant2026-02-1818,13700.0THAKKAR ROOPALOfficer
Grant2026-02-186,07100.0PURDUE DAVID R.Officer
Grant2026-02-182,46000.0CRUM DEMETRIS DOfficer
Grant2025-08-1242,3702,324,41854.9SALEKI-GERHARDT AZITAChief Operating Officer
Sell2025-08-1242,3708,407,055198.4SALEKI-GERHARDT AZITAChief Operating Officer
Sell2025-08-0513,2952,639,253198.5DONOGHOE NICHOLASOfficer
Grant2025-05-091,20300.0FALK THOMAS JDirector
Grant2025-05-091,20300.0AUSTIN ROXANNE SCHUHDirector
Grant2025-05-091,20300.0WADDELL FREDERICK HDirector
Grant2025-05-091,20300.0RAPP EDWARD JDirector
Grant2025-05-091,20300.0TILTON GLENN FLETCHERDirector
Grant2025-05-091,20300.0ALPERN ROBERT JDirector
Grant2025-05-091,20300.0HART BRETT JDirector
Grant2025-05-091,20300.0FREYMAN THOMAS CDirector
Grant2025-05-091,20300.0DAVIS JENNIFER LDirector
Grant2025-05-091,20300.0QUAGGIN SUSAN EDirector
Grant2025-05-091,20300.0BURNSIDE WILLIAM H LDirector
Grant2025-05-091,20300.0MEYER MELODY BDirector
Grant2025-05-091,20300.0ROBERTS REBECCA B.Director

Congressional trading

$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$325012026-01$8001
$160012025-12$0.00
$80012025-11$0.00
$80012025-10$24002
$0.002025-09$0.00
$240022025-08$32002
$240022025-07$24002
$0.002025-06$16001
$0.002025-05$56502
DatePoliticianPartyChamberAmount ($)
Sell2026-01-29Ro KhannaDHouse$15,001 - $50,000
Buy2026-01-23Ro KhannaDHouse$1,001 - $15,000
Sell2025-12-18Julie JohnsonDHouse$1,001 - $15,000
Sell2025-12-08Julia LetlowRHouse$1,001 - $15,000
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-08-22John BoozmanRSenate$1,001 - $15,000
Sell2025-08-14Julie JohnsonDHouse$1,001 - $15,000
Sell2025-08-11John BoozmanRSenate$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-11Ritchie TorresDHouse$1,001 - $15,000
Sell2025-07-11Ritchie TorresDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$15,001 - $50,000
Buy2025-05-22Josh GottheimerDHouse$1,001 - $15,000
Buy2025-05-15Rob BresnahanRHouse$1,001 - $15,000
Buy2025-05-05Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-04-28Julia LetlowRHouse$1,001 - $15,000
Sell2025-04-17Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-17Jefferson ShreveRHouse$50,001 - $100,000
Sell2025-04-09Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$1,001 - $15,000
Buy2025-04-07Jared MoskowitzDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-03Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-03Dwight EvansDHouse$1,001 - $15,000
Buy2025-04-01Josh GottheimerDHouse$1,001 - $15,000
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact